Skip to content

Clinical Study to Establish the Feasibility and Usability of the EndoRings™

EndoRings™ - Clinical Protocol

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01868971
Enrollment
60
Registered
2013-06-05
Start date
2013-04-30
Completion date
2013-10-31
Last updated
2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel Cancer, Colon Cancer, Colorectal Cancer

Keywords

EndoRings

Brief summary

The purpose of this prospective clinical study is to establish the feasibility and usability of the ENDORINGS™ when used during standard colonoscopy procedure.

Detailed description

The EndoAid Ltd. EndoRings is used during endoscopy procedures. The EndoRings is a short silicon rubber tube with flexible circular wings that attaches to the distal end of the endoscope to facilitate endoscopic therapy. The EndoRings is designed to fit specific endoscopes (as designated on the packaging), and is supplied sterile following ETO sterilization and is single use only. Indications for Use: To be attached to the distal end of the endoscope to facilitate endoscopic therapy, to be used for the following: * Keeping the suitable depth of endoscope's view field * Helping the endoscope with being inserted into the gastrointestinal tract Patient Population: The study population is comprised of patients indicated for colonoscopy. Study Design: Single-center study. A single treatment group of 60 patients. No. of Patients: Up to sixty (60) treated patients will be enrolled in the study. Primary Endpoints:The primary endpoint is reaching the cecum of the colon with the ENDORINGS™. Secondary Endpoints / Other Outcomes: 1. Incidence of complications (number of complications) 2. Ability to complete s therapeutic interventions as biopsies, polypectomies, APC etc. 3. Procedure time. 4. Ease of scope insertion, advancement and withdrawal. 5. Ability to center the scope inside the gastrointestinal tract. 6. Subjective evaluation of the additional area screened by the physician (recorded in the source documents by a questionnaire). 7. Patient satisfactory (by a follow up phone-call in which questionnaire with VAS scale will be filled out).

Interventions

DEVICEEndoRings

Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation

Sponsors

EndoAid
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

Any subject who meets all of the following criteria may be included in this study: * Subject between the ages of 18 and 70 * The patient is undergoing colonoscopy for screening, or for surveillance in follow-up of previous polypectomy or for diagnostic workup; * Written informed consent must be available before enrollment in the trial * For women with childbearing potential, adequate contraception

Exclusion criteria

Any subject who meets any of the following criteria will not be included in this study: * Patients with a history of colonic resection; * Patients with inflammatory bowel disease; * Patients with a personal history of polyposis syndrome; * Patients with suspected chronic stricture potentially precluding complete colonoscopy; * Patients with diverticulitis or toxic megacolon; * Patients with a history of radiation therapy to abdomen or pelvis; * Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.24 hours post procedure

Secondary

MeasureTime frameDescription
2. Ability to complete s therapeutic interventions as biopsies, polypectomies, APC etc.24 hours post procedureWhenever a polyp or other abnormality is detected, the endoscopist will perform biopsy, polypectomy or other evaluation or therapy as appropriate. The clinical investigator will use his/her clinical judgment on the safety of polyp removal/biopsy.
3. Procedure time.During procedureProcedural times for each colonoscopy procedure: 1. Time for intubation to the cecum 2. Time for withdrawal from the cecum to the anal verge 3. Total procedure time
4. Ease of scope insertion, advancement and withdrawal.During procedurePhysician's subjective evaluation will be recorded in the source documents by a questionnaire.
1. Incidence of complications (number of complications)24 hours post procedureKnown complications include: * Perforation; * Severe abdominal pain; * Infection; * Bleeding (other than expected minor bleeding due to therapeutic procedures e.g. polypectomy); * Inducing inflammation of diverticulum * Arrhythmia, bradycardia, hypotension, hypoxia * Death A complication is defined as any one of the above complications as well as any other unexpected complication requiring medical intervention beyond that of the standard procedure. All adverse events will be reported and treated as per the standard clinical practices. A telephone call should be made to the patient at 24 hour post- procedure, to assess post-examination adverse events.
6. Subjective evaluation of the additional area screened by the physician.During procedurePhysician's subjective evaluation will be recorded in the source documents by a questionnaire.
7. Patient satisfactory.During procedureA telephone call should be made to the patient at 24 hour post- procedure, to assess patient satisfactory by completing a VAS scale questionnaire.
5. Ability to center the scope inside the gastrointestinal tract.During procedurePhysician's subjective evaluation will be recorded in the source documents by a questionnaire.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026